

Dhifaf Sarhan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7274613/publications.pdf>

Version: 2024-02-01

37
papers

1,670
citations

394286

19
h-index

477173

29
g-index

39
all docs

39
docs citations

39
times ranked

2821
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity. <i>Clinical Cancer Research</i> , 2014, 20, 4096-4106.	3.2	230
2	Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity. <i>Frontiers in Immunology</i> , 2015, 6, 605.	2.2	153
3	Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2016, 76, 5696-5706.	0.4	146
4	GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity. <i>Cancer Research</i> , 2017, 77, 5664-5675.	0.4	114
5	Distinct developmental pathways from blood monocytes generate human lung macrophage diversity. <i>Immunity</i> , 2021, 54, 259-275.e7.	6.6	107
6	Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function. <i>Cancer Research</i> , 2021, 81, 956-967.	0.4	104
7	Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 32005-32016.	3.3	89
8	161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS. <i>Blood Advances</i> , 2018, 2, 1459-1469.	2.5	85
9	Selenium stimulates the antitumour immunity: Insights to future research. <i>European Journal of Cancer</i> , 2021, 155, 256-267.	1.3	81
10	Adaptive NK Cells Resist Regulatory T-cell Suppression Driven by IL37. <i>Cancer Immunology Research</i> , 2018, 6, 766-775.	1.6	75
11	Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 483-494.	2.0	74
12	Early Reconstitution of NK and $\gamma\delta$ T Cells and Its Implication for the Design of Post-Transplant Immunotherapy. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1152-1162.	2.0	56
13	Doxorubicin sensitizes human tumor cells to NK cell-mediated killing by augmented TRAIL receptor signaling. <i>International Journal of Cancer</i> , 2013, 133, 1643-1652.	2.3	54
14	HER2/HER3 Signaling Regulates NK Cell-Mediated Cytotoxicity via MHC Class I Chain-Related Molecule A and B Expression in Human Breast Cancer Cell Lines. <i>Journal of Immunology</i> , 2012, 188, 2136-2145.	0.4	51
15	Mesenchymal stromal cells shape the MDS microenvironment by inducing suppressive monocytes that dampen NK cell function. <i>JCI Insight</i> , 2020, 5, .	2.3	35
16	Dendritic cell regulation of NK cell responses involves lymphotoxin- α , IL-12, and TGF- β 2. <i>European Journal of Immunology</i> , 2015, 45, 1783-1793.	1.6	34
17	Enhanced stimulation of human tumor-specific T cells by dendritic cells matured in the presence of interferon- γ and multiple toll-like receptor agonists. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1333-1344.	2.0	31
18	A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1359-1368.	2.0	27

#	ARTICLE	IF	CITATIONS
19	Activated monocytes augment TRAIL-mediated cytotoxicity by human NK cells through release of IFN γ . European Journal of Immunology, 2013, 43, 249-257.	1.6	23
20	Zoledronic acid inhibits NFAT and IL-2 signaling pathways in regulatory T cells and diminishes their suppressive function in patients with metastatic cancer. Oncoimmunology, 2017, 6, e1338238.	2.1	19
21	Regulation of TRAIL-Receptor Expression by the Ubiquitin-Proteasome System. International Journal of Molecular Sciences, 2014, 15, 18557-18573.	1.8	18
22	Independent control of natural killer cell responsiveness and homeostasis at steady-state by CD11c+ dendritic cells. Scientific Reports, 2016, 6, 37996.	1.6	18
23	FOXP3+ T cells in uterine sarcomas are associated with favorable prognosis, low extracellular matrix expression and reduced YAP activation. Npj Precision Oncology, 2021, 5, 97.	2.3	9
24	Phosphodiesterase 4A confers resistance to PGE $_{2}$ -mediated suppression in CD25 ⁺ /CD54 ⁺ NK cells. EMBO Reports, 2021, 22, e51329.	2.0	8
25	CD16-IL15-CD33 Trispecific Killer Engager (TriKE) Overcomes Cancer-Induced Immune Suppression and Induces Natural Killer Cell-Mediated Control of MDS and AML Via Enhanced Killing Kinetics. Blood, 2016, 128, 4291-4291.	0.6	8
26	Sex dimorphism in the tumor microenvironment – From bench to bedside and back. Seminars in Cancer Biology, 2022, 86, 166-179.	4.3	8
27	Assessing Canonical and Adaptive Natural Killer Cell Function in Suppression Assays In Vitro. Methods in Molecular Biology, 2019, 1913, 153-166.	0.4	5
28	Development and Scale-up of a Novel GMP Method for Enrichment and Expansion of Terminally Differentiated Adaptive Natural Killer Cells (FATE-NK100) with Enhanced Anti-Tumor Function. Blood, 2016, 128, 1225-1225.	0.6	3
29	Opposing consequences of signaling through EGF family members. Oncoimmunology, 2012, 1, 1200-1201.	2.1	2
30	Inhibition of tumor-derived prostaglandin-e $_{2}$ prevents the induction of human myeloid-derived suppressor cells (MDSCs) and rescues anti-tumor immunity. , 2014, 2, .		2
31	Targeting MARCO and IL-37R on anti-inflammatory macrophages in lung cancer blocks regulatory T cells and shift balance to support cytotoxic lymphocyte function. , 2020, , .		1
32	Natural Killer Cells: What Have We Learned?. Advances and Controversies in Hematopoietic Transplantation and Cell Therapy, 2019, , 181-200.	0.0	0
33	Regulation of Natural Killer Cell Responses By Dendritic Cells Via Lymphotoxin-Alpha, Interleukin-12, and Tumor Growth Factor-Beta. Blood, 2014, 124, 4140-4140.	0.6	0
34	Abstract B071: Enhanced IL-12 production and T cell stimulation ability by dendritic cells matured in presence of GMP-grade Toll-like receptor ligands and IFN γ . , 2016, , .		0
35	Haploidentical Natural Killer Cell Infusion Induces Remission in Non-Hodgkin Lymphoma and Overcomes Resistance to Rituximab. Blood, 2016, 128, 3030-3030.	0.6	0
36	Abstract 3752: FATE-NK100: A novel NK cell-mediated cancer therapy. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
37	885â€¦Targeting FPR2 as a novel approach for immunotherapy in pancreatic cancer female patients - studies of sexual immune dimorphism in the tumor microenvironment. , 2021, 9, A927-A927.		0